ENANTA PHARMACEUTICALS ($ENTA) posted quarterly earnings results on Monday, November 17th. The company reported earnings of -$0.87 per share, beating estimates of -$1.04 by $0.17. The company also reported revenue of $15,130,000, missing estimates of $16,275,120 by $-1,145,120.
You can see Quiver Quantitative's $ENTA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ENANTA PHARMACEUTICALS Hedge Fund Activity
We have seen 55 institutional investors add shares of ENANTA PHARMACEUTICALS stock to their portfolio, and 66 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANUS HENDERSON GROUP PLC added 1,423,171 shares (+271.7%) to their portfolio in Q3 2025, for an estimated $17,035,356
- COMMODORE CAPITAL LP added 800,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $9,576,000
- MARSHALL WACE, LLP removed 582,023 shares (-67.9%) from their portfolio in Q3 2025, for an estimated $6,966,815
- MILLENNIUM MANAGEMENT LLC removed 510,509 shares (-35.0%) from their portfolio in Q3 2025, for an estimated $6,110,792
- POINT72 ASSET MANAGEMENT, L.P. added 300,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $3,591,000
- STONEPINE CAPITAL MANAGEMENT, LLC removed 299,066 shares (-49.5%) from their portfolio in Q3 2025, for an estimated $3,579,820
- SIO CAPITAL MANAGEMENT, LLC removed 178,774 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $2,139,924
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ENANTA PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $ENTA in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 11/14/2025
- WestPark Capital issued a "Buy" rating on 09/30/2025
- Evercore ISI Group issued a "Outperform" rating on 09/15/2025
- JMP Securities issued a "Market Outperform" rating on 08/12/2025
- HC Wainwright & Co. issued a "Buy" rating on 07/28/2025
To track analyst ratings and price targets for ENANTA PHARMACEUTICALS, check out Quiver Quantitative's $ENTA forecast page.
ENANTA PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $ENTA recently. We have seen 5 analysts offer price targets for $ENTA in the last 6 months, with a median target of $20.0.
Here are some recent targets:
- Anupam Rama from JP Morgan set a target price of $17.0 on 11/14/2025
- Ed Arce from WestPark Capital set a target price of $28.0 on 09/30/2025
- Liisa Bayko from Evercore ISI Group set a target price of $12.0 on 09/15/2025
- Roy Buchanan from JMP Securities set a target price of $25.0 on 08/12/2025
- Brandon Folkes from HC Wainwright & Co. set a target price of $20.0 on 07/28/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
